Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04307953

Saracatinib Trial TO Prevent FOP — STOPFOP  

Fibrodysplasia Ossificans Progressiva Clinical Trial

Official title:
Saracatinib Trial TO Prevent FOP

Clinical Trial Summary

This is a phase 2 study, designed as a European multicentre 6-month double blind random-ized controlled trial (RCT) of AZD0530 versus matched placebo, followed by a 12 month trial comparing open-label extended AZD0530 treatment with historical control data. Study population: Male and female adult patients aged 18 years and older with a diagnosis of FOP who meet the inclusion (active disease) and exclusion criteria will be eligible for participation in this study. The total number of enrolled patients will be 20. Intervention: Patients will be randomized to receive either AZD0530 100mg once daily or matched placebo, taken orally for the first 6 months, immediately followed by an open-label extension in which all patients will receive AZD0530 100mg once daily oral dose for a further 12 months. Endpoints: Endpoints include objective change in heterotopic bone volume measured by low-dose whole-body computer tomography (CT) , [18F] NaF Positron Emission Tomography (PET) activity and patient reported outcome measures.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Fibrodysplasia Ossificans Progressiva
Clinical Trial Details
NCT number NCT04307953
Study type Interventional
Source Amsterdam UMC, location VUmc
Contact Vincent A. Verheij, MD
Phone +31204444444
Email v.a.verheij@amsterdamumc.nl
Status Recruiting
Phase Phase 2
Start date August 5, 2020
Completion date May 6, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT02279095 - An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP) Phase 2
Completed NCT03312634 - An Efficacy and Safety Study of Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva. Phase 3
Completed NCT02979769 - An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in People With Fibrodysplasia Ossificans Progressiva (FOP) in France Phase 2
Recruiting NCT05394116 - A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP) Phase 3
Completed NCT02066324 - Urine Sample Collection From FOP Patients N/A
Completed NCT02190747 - An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects Phase 2
Completed NCT04829773 - Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects Phase 1
Completed NCT04665323 - An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.
Completed NCT03188666 - A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva Phase 2
Terminated NCT02521792 - In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects Phase 2
Completed NCT02322255 - A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)
Recruiting NCT05039515 - A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP). Phase 2
Not yet recruiting NCT06089616 - A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Completed NCT04818398 - Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects Phase 1